在挪威对成年人肥胖的药理治疗 2004-202222年
相关实验视频
Updated: Jul 2, 2025

04:48
Control of Eating Behavior Using a Novel Feedback System
Published on: May 8, 2018
11.0K
Paz Lopez-Doriga Ruiz1, Øystein Karlstad1, Kjersti Nøkleby2
1Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
Diabetes, obesity & metabolism
|February 29, 2024
概括
挪威的抗肥胖药物使用从2017年到2022年大幅增加,特别是在40-59岁的女性中. 市场变化和补偿政策影响了处方药使用的趋势.
科学领域:
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 由于市场撤销和新药批准,抗肥胖药物的使用发生了变化.
- 了解处方趋势对于公共卫生战略和资源分配至关重要.
研究的目的:
- 分析2004年至2022年挪威使用抗肥胖药物的趋势.
- 调查与这些药物相关的人口结构模式和成本影响.
主要方法:
- 利用挪威处方药登记册评估成年人 (18-79岁) 年度抗肥胖药物使用情况.
- 按性别和年龄组分层次的患病率,并对2017年以来的治疗开始和药物成本进行了额外的分析.
主要成果:
- 在2009年退出市场后,患病率下降,但在2017年后,随着新药的批准 (布普罗-纳尔特雷,利拉格卢提德),患病率上升.
- 在2022年,布洛普-纳尔特雷克松,利拉格卢提德和西马格卢提德的使用率分别达到1.04%,0.91%和0.68%,主要在女性中.
- 药品成本从2017年的110万欧元升至2022年的9180万欧元.
结论:
- 最近,挪威的抗肥胖药物使用明显增加,特别是在40-59岁的女性中.
- 药物可用性和补偿政策对最近的使用模式产生了重大影响.
相关概念视频
Obesity
498
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
498
Prescription, Nonprescription and Orphan Drugs
728
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
728
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
137
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
137
Analysis of Population Pharmacokinetic Data
254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254
Antidepressant Drugs: MAOIs and Other Agents
229
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
229
Drug Control Governance: Regulatory Bodies and Their Impact
158
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
158

